{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:00:24Z","timestamp":1784224824130,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.hoc.2007.08.009","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T15:08:55Z","timestamp":1196953735000},"page":"1035-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Pathophysiology of Multiple Myeloma Bone Disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Suzanne","family":"Lentzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.hoc.2007.08.009_bib1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.009_bib2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1359\/jbmr.2005.20.5.886","article-title":"How many women have osteoporosis? JBMR Anniversary Classic. JBMR, Volume 7, Number 9, 1992","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.hoc.2007.08.009_bib3","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428190309178765","article-title":"New insights in myeloma-induced osteolysis","volume":"44","author":"Barille-Nion","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2007.08.009_bib4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL)","volume":"32","author":"Giuliani","year":"2004","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2004","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"10.1016\/j.hoc.2007.08.009_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.009_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.1990.tb07904.x","article-title":"Osteoblast stimulation in multiple myeloma lacking lytic bone lesions","volume":"76","author":"Bataille","year":"1990","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0609.1997.tb00932.x","article-title":"Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens","volume":"58","author":"Vejlgaard","year":"1997","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2007.08.009_bib9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","article-title":"Cell biology of the osteoclast","volume":"27","author":"Roodman","year":"1999","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.009_bib10","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1530\/eje.0.1390152","article-title":"Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis","volume":"139","author":"Hofbauer","year":"1998","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.009_bib12","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.hoc.2007.08.009_bib13","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/bbrc.1998.8610","article-title":"Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone","volume":"246","author":"Tsukii","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.009_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis","volume":"192","author":"Min","year":"2000","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.009_bib17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"4920","key":"10.1016\/j.hoc.2007.08.009_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1126\/science.2528207","article-title":"Osteoclastic bone resorption by a polarized vacuolar proton pump","volume":"245","author":"Blair","year":"1989","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jbmr.5650080215","article-title":"Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: a structure-function analysis","volume":"8","author":"Horton","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"Pt 4","key":"10.1016\/j.hoc.2007.08.009_bib20","first-page":"1537","article-title":"Scanning electron microscopy in bone pathology: review of methods, potential and applications","author":"Boyde","year":"1986","journal-title":"Scan Electron Microsc"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.009_bib21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.1995.tb05609.x","article-title":"Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo","volume":"90","author":"Bataille","year":"1995","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.009_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"issue":"15","key":"10.1016\/j.hoc.2007.08.009_bib23","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","article-title":"Biology of osteoclast activation in cancer","volume":"19","author":"Roodman","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jbmr.5650040116","article-title":"Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro","volume":"4","author":"Pfeilschifter","year":"1989","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.009_bib25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0889-8588(05)70115-5","article-title":"The role of interleukin-1 beta in the pathogenesis of multiple myeloma","volume":"13","author":"Lust","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1365-2141.1999.01193.x","article-title":"Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma","volume":"104","author":"Sati","year":"1999","journal-title":"Br J Haematol"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2007.08.009_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10428199609045719","article-title":"Cytokine expression in multiple myeloma and monoclonal gammopathy: analysis by reverse transcription\/polymerase chain reaction and quantitative PCR","volume":"24","author":"Soutar","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.009_bib28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.leu.2402481","article-title":"Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells","volume":"16","author":"Cheung","year":"2002","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.009_bib29","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1172\/JCI117990","article-title":"Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo","volume":"95","author":"de la Mata","year":"1995","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.009_bib30","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.4049\/jimmunol.144.11.4226","article-title":"IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release","volume":"144","author":"Kurihara","year":"1990","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0889-8588(05)70413-5","article-title":"Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma","volume":"11","author":"Teoh","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"issue":"13","key":"10.1016\/j.hoc.2007.08.009_bib32","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2007.08.009_bib33","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.009_bib34","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jlb.59.1.61","article-title":"The role of MIP-1 alpha in inflammation and hematopoiesis","volume":"59","author":"Cook","year":"1996","journal-title":"J Leukoc Biol"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.009_bib36","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.009_bib37","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.4049\/jimmunol.154.11.6065","article-title":"Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts","volume":"154","author":"Fuller","year":"1995","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.009_bib38","first-page":"399","article-title":"Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment","volume":"76","author":"Kukita","year":"1997","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671.014k24_671_675","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","article-title":"Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma","volume":"125","author":"Hashimoto","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04040.x","article-title":"Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM","volume":"120","author":"Uneda","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2007.08.009_bib42","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2007.08.009_bib43","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2007.08.009_bib44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/asheducation-2002.1.214","article-title":"Multiple myeloma","volume":"2002","author":"Anderson","year":"2002","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.009_bib45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0009-9260(81)80043-8","article-title":"Multiple myeloma: radiology or bone scanning?","volume":"32","author":"Leonard","year":"1981","journal-title":"Clin Radiol"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1359\/jbmr.1999.14.2.256","article-title":"Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice","volume":"14","author":"Hjorth-Hansen","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.009_bib47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2004.05084.x","article-title":"Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells","volume":"126","author":"Silvestris","year":"2004","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.009_bib48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1302\/0301-620X.71B2.2925748","article-title":"Does myeloma secrete an osteoblast inhibiting factor?","volume":"71","author":"Evans","year":"1989","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.hoc.2007.08.009_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","article-title":"Wnt signaling in osteoblasts and bone diseases","volume":"341","author":"Westendorf","year":"2004","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0006-291X(02)02951-0","article-title":"Activated beta-catenin induces osteoblast differentiation of C3H10T1\/2 cells and participates in BMP2 mediated signal transduction","volume":"301","author":"Bain","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"26","key":"10.1016\/j.hoc.2007.08.009_bib51","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.009_bib52","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2007.08.009_bib53","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2007.08.009_bib54","doi-asserted-by":"crossref","unstructured":"Oshima T, Abe M, Asano J, et\u00a0al. Myeloma cells suppress osteoblast differentiation by secreting a soluble wnt inhibitor, sFRP-2 [abstract 2356]. Presented at the 46th annual meeting of the American Society of Hematology. San Diego (CA), December 4\u20137, 2004.","DOI":"10.1182\/blood.V104.11.2356.2356"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.009_bib55","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.V98.3.771","article-title":"Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays","volume":"98","author":"De Vos","year":"2001","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2007.08.009_bib56","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2003-01-0016","article-title":"Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis","volume":"102","author":"Davies","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2249.1993.tb05943.x","article-title":"Cytokines involved in the progression of multiple myeloma","volume":"92","author":"Merico","year":"1993","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.009_bib58","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.009_bib59","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.009_bib60","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1172\/JCI0215687","article-title":"Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency","volume":"110","author":"Weitzmann","year":"2002","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.009_bib61","first-page":"567","article-title":"Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma","volume":"89","author":"Abildgaard","year":"2004","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.009_bib62","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured cell mass with presenting clinical features, response to treatment and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2002.00505.x","article-title":"Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma","volume":"69","author":"Jakob","year":"2002","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2007.08.009_bib64","first-page":"3047","article-title":"Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography","volume":"9","author":"Jakob","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.hoc.2007.08.009_bib65","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.009_bib66","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.ejca.2006.02.015","article-title":"Proteasome inhibition in multiple myeloma","volume":"42","author":"Kropff","year":"2006","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.009_bib67","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.009_bib68","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.leu.2403758","article-title":"High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation","volume":"19","author":"Shimazaki","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.009_bib70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2007.08.009_bib71","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.009_bib72","first-page":"37","article-title":"[Therapeutic agents for disorders of bone and calcium metabolism\u2014Denosumab, a fully human monoclonal antibody-targeting RANKL as a therapy for cancer-induced bone diseases]","volume":"17","author":"Mera","year":"2007","journal-title":"Clin Calcium"},{"key":"10.1016\/j.hoc.2007.08.009_bib73","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","article-title":"Thalidomide derivative CC-4047 inhibits osteoclast formation by down regulation of PU.1","volume":"107","author":"Anderson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2007.08.009_bib74","doi-asserted-by":"crossref","unstructured":"Feng R, Oton A, Patrene K, et\u00a0al. Combination of the proteasome inhibitor bortezomib and a histone deacetylase inhibitor PXD101 results in synergistic inhibition of osteoclastogenesis and multiple myeloma growth in vitro and in vivo [abstract 507]. Presented at the American Society of Hematology Annual Meeting. Orlando (FL), December 9\u201312, 2006.","DOI":"10.1182\/blood.V108.11.507.507"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.009_bib75","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood-2006-07-027458","article-title":"SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-{kappa}B activity, resulting in strong inhibition of osteoclast formation\/activity and multiple myeloma cell growth","volume":"109","author":"Feng","year":"2007","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858807001177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858807001177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:50:14Z","timestamp":1760183414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858807001177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0889858807001177"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2007.08.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology of Multiple Myeloma Bone Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2007.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}